Evaluation of Efficacy and Safety of the Dosage Adjustment of Aprovel® (Irbesartan) in Hypertensive Outpatients in Current Clinical Practice
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 4
Locations
Tunisia
Study Type
Interventional
Intervention
Irbesartan
Irbesartan
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
- Mild to Moderate hypertension (90mmHg<DBP<110mmHg and 140mmHg<SBP<180mmHg)
- Or new diagnosed hypertension (after 2 visits within 1 month), never treated before and responding to required conditions for a treatment with irbesartan, after an adapted but insufficient diet
- Or a patient having already been treated with a non-satisfying antihypertensive treatment stopped since at least 2 weeks before the inclusion
- A minimum exam labs as required by WHO-ISH within the month before the inclusion
Exclusion Criteria:
- Severe Arterial Hypertension (PAS > than or = to 180 mm Hg or PAD > than or = to 110 mmHg)
- Isolated Systolic Hypertension
- Secondary Hypertension
- Bilateral renal arterial stenosis or renal arterial stenosis
- Non surgically sterilised woman or non post-menopausal woman
- Confirmed sodium depletion
- Irbesartan hypersensitivity
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Sites / Locations
- Sanofi-Aventis
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
1
2
Arm Description
Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks: • 150mg/day for normalized patients and patients responding non normalized randomized in the group A
• Or 300 mg/day for non responding patients and responding patients non normalized randomized in the group B
Outcomes
Primary Outcome Measures
To Evaluate the efficacy of two regimens of irbesartan in patients responding but not normalized (schema N°1: maintenance 150mg/day, schema n°2: 300mg/day for 6 more weeks)
Secondary Outcome Measures
• To evaluate the percentage of patients with DBP<90 mmHg
• To evaluate rate of adverse events
• To evaluate the percentage of patients with SBP<140 mmHg
Full Information
NCT ID
NCT00564187
First Posted
November 20, 2007
Last Updated
November 27, 2007
Sponsor
Sanofi
Collaborators
Bristol-Myers Squibb
1. Study Identification
Unique Protocol Identification Number
NCT00564187
Brief Title
Evaluation of Efficacy and Safety of the Dosage Adjustment of Aprovel® (Irbesartan) in Hypertensive Outpatients in Current Clinical Practice
Official Title
Prospective, Multicentric, Randomized, Open, Comparative Phase IV Study Evaluating the Efficacy and Safety of the Dosage Adjustment of Aprovel® (Irbesartan) in Hypertensive Outpatients in Current Clinical Practice
Study Type
Interventional
2. Study Status
Record Verification Date
November 2007
Overall Recruitment Status
Completed
Study Start Date
February 2003 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
December 2004 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Sanofi
Collaborators
Bristol-Myers Squibb
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Primary:
To evaluate the efficacy of two regimens of irbesartan in patients responding but not normalized at 6 weeks of treatment (schema N°1: maintenance 150 mg/day, schema n°2: 300 mg/day for 6 more weeks)
Secondary:
To evaluate the percentage of patients with DBP < 90 mmHg at 6 and 12 weeks
To evaluate the percentage of patients with SBP < 140 mmHg at 6 and 12 weeks
To evaluate rate of adverse events during the study
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
115 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Active Comparator
Arm Description
Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:
• 150mg/day for normalized patients and patients responding non normalized randomized in the group A
Arm Title
2
Arm Type
Active Comparator
Arm Description
• Or 300 mg/day for non responding patients and responding patients non normalized randomized in the group B
Intervention Type
Drug
Intervention Name(s)
Irbesartan
Intervention Description
Irbesartan: 150mg tablets
Dosage: Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:
• 150mg/day for normalized patients and patients responding non normalized randomized in the group A
Intervention Type
Drug
Intervention Name(s)
Irbesartan
Intervention Description
Irbesartan: 150mg tablets
Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:
• Or 300 mg/day for non responding patients and responding patients non normalized randomized in the group B
Primary Outcome Measure Information:
Title
To Evaluate the efficacy of two regimens of irbesartan in patients responding but not normalized (schema N°1: maintenance 150mg/day, schema n°2: 300mg/day for 6 more weeks)
Time Frame
at 6 weeks of treatment
Secondary Outcome Measure Information:
Title
• To evaluate the percentage of patients with DBP<90 mmHg
Time Frame
at 6 and 12 weeks
Title
• To evaluate rate of adverse events
Time Frame
during the study duration
Title
• To evaluate the percentage of patients with SBP<140 mmHg
Time Frame
at 6 and 12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Mild to Moderate hypertension (90mmHg<DBP<110mmHg and 140mmHg<SBP<180mmHg)
Or new diagnosed hypertension (after 2 visits within 1 month), never treated before and responding to required conditions for a treatment with irbesartan, after an adapted but insufficient diet
Or a patient having already been treated with a non-satisfying antihypertensive treatment stopped since at least 2 weeks before the inclusion
A minimum exam labs as required by WHO-ISH within the month before the inclusion
Exclusion Criteria:
Severe Arterial Hypertension (PAS > than or = to 180 mm Hg or PAD > than or = to 110 mmHg)
Isolated Systolic Hypertension
Secondary Hypertension
Bilateral renal arterial stenosis or renal arterial stenosis
Non surgically sterilised woman or non post-menopausal woman
Confirmed sodium depletion
Irbesartan hypersensitivity
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chokri Jeribi
Organizational Affiliation
Sanofi
Official's Role
Study Director
Facility Information:
Facility Name
Sanofi-Aventis
City
Megrine
Country
Tunisia
12. IPD Sharing Statement
Learn more about this trial
Evaluation of Efficacy and Safety of the Dosage Adjustment of Aprovel® (Irbesartan) in Hypertensive Outpatients in Current Clinical Practice
We'll reach out to this number within 24 hrs